Literature DB >> 32077744

miR-634 Decreases the Radioresistance of Human Breast Cancer Cells by Targeting STAT3.

Bilan Yang1,2, Feng Kuai3, Zhijun Chen2, Deshun Fu2, Jun Liu4, Yiwei Wu1, Jun Zhong4.   

Abstract

Background: Breast cancer is the second most common cancer in women, which is usually treated by radiation therapy. However, resistance of cancer cells to radiation therapy has made treatment difficult. Therefore, finding effective ways to reduce the radiation resistance of cancer cells is an urgent problem to be solved. Materials and
Methods: MCF-7 and MDA-MB-231 cells (on accepting radiation) were established to model radiation resistance, namely MCF-7/R and MDA-MB-231/R. The authors then examined the expression of miR-634 through quantitative reverse transcription-polymerase chain reaction. MCF-7/R and MDA-MB-231/R cells were transfected with overexpressed miR-634 mimics. In addition, TargetScan predicted which binding site was targeted by miR-634, and luciferase assay detected the signal transducer and activator of transcription 3 (STAT3) 3'UTR luciferase activity after transfection of mimics expressing miR-634 into HEK-293 cells. 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT), flow cytometry, and western blot assays were used for examination of different levels of biological function.
Results: miRNA-634 expression was significantly decreased in radiated MCF-7 and MDA-MB-231 cells. When miR-634 mimic was transfected into radiation-resistant MCF-7/R and MDA-MB-231/R cells, the survival rate of radiation-tolerant cells was significantly reduced. Moreover, STAT3 was found to directly interact with miR-634, and further studies demonstrated that miR-634 negatively regulated STAT3.
Conclusion: miR-634 was able to regulate STAT3 and enhance the sensitivity of breast cancer cells to radiation; these results might shed new light on radiation therapy for breast cancer.

Entities:  

Keywords:  MCF-7; STAT3; breast cancer; miR-634; radiation therapy

Year:  2020        PMID: 32077744     DOI: 10.1089/cbr.2019.3220

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  6 in total

Review 1.  Radiation therapy for triple-negative breast cancer: emerging role of microRNAs as biomarkers and radiosensitivity modifiers. A systematic review.

Authors:  Nina Radosevic-Robin; Yazid Belkacemi; Nhu Hanh To; Hoang Quy Nguyen; Allan Thiolat; Bisheng Liu; José Cohen
Journal:  Breast Cancer Res Treat       Date:  2022-04-09       Impact factor: 4.872

Review 2.  Role of non-coding RNAs in response of breast cancer to radiation therapy.

Authors:  Nastaran Masoudi-Khoram; Parviz Abdolmaleki
Journal:  Mol Biol Rep       Date:  2022-02-25       Impact factor: 2.742

3.  Hsa_circ_0084927 Regulates Cervical Cancer Advancement via Regulation of the miR-634/TPD52 Axis.

Authors:  Peijing Shi; Xiaoyong Zhang; Chunxiang Lou; Yunxia Xue; Ruibao Guo; Shuzhen Chen
Journal:  Cancer Manag Res       Date:  2020-10-02       Impact factor: 3.989

4.  The expression and clinical significance of signal transducer and activator of transcription 3, tumor necrosis factor α induced protein 8-like 2, and runt-related transcription factor 1 in breast cancer patients.

Authors:  Daitian Lan; Xuchu Jin; Maode Li; Li He
Journal:  Gland Surg       Date:  2021-03

Review 5.  Advances on Natural Abietane, Labdane and Clerodane Diterpenes as Anti-Cancer Agents: Sources and Mechanisms of Action.

Authors:  Rosaria Acquaviva; Giuseppe A Malfa; Monica R Loizzo; Jianbo Xiao; Simone Bianchi; Rosa Tundis
Journal:  Molecules       Date:  2022-07-26       Impact factor: 4.927

6.  Activated ERK Signaling Is One of the Major Hub Signals Related to the Acquisition of Radiotherapy-Resistant MDA-MB-231 Breast Cancer Cells.

Authors:  Anjugam Paramanantham; Eun Joo Jung; Se-Il Go; Bae Kwon Jeong; Jin-Myung Jung; Soon Chan Hong; Gon Sup Kim; Won Sup Lee
Journal:  Int J Mol Sci       Date:  2021-05-06       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.